Breaking News From Pharma & Bio Ingredients
Carrington Earns European Patent for Delivery System
Posted on 2005-11-30 12:55:00
Carrington Laboratories, Inc. today announced that the European Patent Office has issued European Patent No. EP 1 086 141 B1 titled "Aloe Pectins" relating to the Company's proprietary GelSite® polymer technology. DelSite Biotechnologies, Inc., Carrington's wholly-owned subsidiary, is developing and commercializing GelSite polymer as a controlled-release drug delivery technology for pharmaceutical and vaccine products.
The newly issued patent describes the basic composition and process of manufacturing high-molecular-weight and low-molecular-weight pectins from Aloe vera. The claims of this patent are broadly applicable to any use of DelSite's Aloe pectins, including use in pharmaceutical compositions including proteins, peptides, vaccine antigens and other pharmacological substances.
"DelSite continues to build a strong intellectual property estate around our proprietary drug delivery technologies and we are pleased to receive the first European patent for GelSite polymer," said Kenneth Yates, president of DelSite Biotechnologies. "GelSite polymer has unique functional properties such as in situ gellation and the ability to stabilize many proteins that make it an attractive basis for novel drug delivery systems, including the GelVac(TM) nasal powder vaccine delivery system."
DelSite's most advanced delivery platform is the GelVac nasal powder vaccine delivery system based on GelSite polymer. GelVac is a simple and broad nasal powder vaccine delivery platform suitable for many different classes of vaccine antigens. In May 2005, DelSite announced results of a Phase I clinical trial involving 15 healthy volunteers that demonstrated that the GelSite polymer and the GelVac system was safe and well tolerated and that doses were consistently and reproducibly delivered to the nasal cavity.
A Drug Master File (DMF) for use of GelSite polymer in mucosal applications was recently filed with the FDA. Currently, preclinical development is progressing for a GelVac nasal powder avian influenza (bird flu) vaccine.
Subscribe via RSS
